

SUPPLEMENTARY INFORMATION

Table S1. Patient flow by dose group

Table S2. PK parameters of utomilumab following multiple dosing

Figure S1. Partial response in a patient with anaplastic thyroid carcinoma (utomilumab 3.6 mg/kg + pembrolizumab 2 mg/kg) at cycle 4 versus baseline.

Figure S2. Mean concentration–time profile for pembrolizumab

SUPPLEMENTARY INFORMATION

Supplementary Table S1. Patient flow by dose group

	Pembrolizumab 2 mg/kg + Utomilumab mg/kg					
	0.45	0.9	1.8	3.6	5.0	Total
Assigned to study						
treatment, <i>n</i>	5	3	3	3	9	23
Treated, <i>n</i>	5	3	3	3	9	23
Discontinued, <i>n</i>	4	3	2	3	8	20
Ongoing, <i>n</i>	1	0	1	0	1	3
Analyzed for safety, <i>n</i>	5	3	3	3	9	23
Analyzed for response, <i>n</i>	5	3	3	3	9	23


Supplementary Table S2. PK parameters of utomilumab following multiple dosing

Dose	<i>n</i>	C_{max}	AUC_{tau}	CL	V_{ss}	<i>t</i>_½	<i>t</i>_{max}
(mg/kg)		(μg/mL)	(μg•h/mL)	(mL/h/kg)	(mL/kg)	(h)	(h)
0.45	4	7.63 (25)	1093 (32)	0.412 (32)	101 (45)	179 (± 24)	1.4 (1.0-2.0)
0.9	1	18.7	1800	0.500	112	173	5.4
1.8	3	29.8 (16)	3477 (41)	0.518 (41)	104 (18)	145 (± 32)	1.1 (1.0-2.0)
3.6	3	60.4 (39)	9253 (67)	0.389 (66)	93.2 (99)	175 (± 47)	1.1 (1.1-1.3)
5.0	4	92.6 (16)	10480 (25)	0.476 (25)	105 (13)	165 (± 50)	1.2 (1.0-6.0)


Geometric mean (geometric %CV) is reported for C_{max}, AUC_{tau}, CL, and V_{ss}; arithmetic mean (± SD) for *t*_½ and median (range) for *t*_{max}. Two patients were excluded for AUC_{tau}, CL, V_{ss} and *t*_{1/2} due to very limited, quantifiable data points. AUC_{tau}, area under the concentration–time curve over dosing interval; CL, clearance; C_{max}, maximum observed concentration; CV, coefficient of variation; SD, standard deviation; *t*_½, terminal phase serum half-life; *t*_{max}, time to C_{max}; V_{ss}, steady-state volume of distribution.

Supplementary Figure S1. Partial response in a patient with anaplastic thyroid carcinoma (utomilumab 3.6 mg/kg + pembrolizumab 2 mg/kg) at cycle 4 versus baseline.

Baseline: 12/12/14



Cycle 4: 3/02/15



Baseline



Cycle 4: 3/10/15



Supplementary Figure S2. Mean concentration–time profile for pembrolizumab

